Symplicity Spyral Renal Denervation System
Medtronic, Inc. · Decision date Jul 16, 2026
What did the FDA approve?
FDA records P220026/S017 as a supplement to PMA P220026, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Jul 16, 2026.
FDA approval order statement
approval for the Symplicity G3 Generator to use updated software version v2.04.00.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Cardiovascular
- Decision date
- Jul 16, 2026
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P220026/S017
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic, Inc.
- Product code
- QYI
- Decision code
- APPR
- Decision date
- Jul 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Ablation catheter, renal denervation.
- Applicant
- Medtronic, Inc.
- Product code
- QYI
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P220026. Subsequent supplements may change the device or its indications.
FDA decision timeline
P220026 · Original PMA
Symplicity Spyral Renal Denervation System
P220026/S015 · Related supplement
Symplicity Spyral Multi-Electrode Renal Denervation Catheter
P220026/S016 · Related supplement
Symplicity Spyral Renal Denervation Catheter
P220026/S017 received
Application receipt date recorded by FDA.
P220026/S017 · FDA decision
Real-Time Process
P220026/S014 · Related supplement
Symplicity Spyral Renal Denervation System
P220026/S019 · Related supplement
Symplicity G3 Renal Denervation RF Generator
Timeline entries are records held by MedtechLedger for P220026. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P220026
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA approval | Nov 17, 2023 | FDA | |
| Medtronic, Inc. | PMA supplement | Feb 27, 2026 | FDA | |
Symplicity Spyral Renal Denervation CatheterP220026/S016 | Medtronic, Inc. | PMA supplement | Mar 25, 2026 | FDA |
Symplicity Spyral Renal Denervation SystemP220026/S014 | Medtronic, Inc. | PMA supplement | Sep 10, 2026 | FDA |
Symplicity G3 Renal Denervation RF GeneratorP220026/S019 | Medtronic, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Explore the linked device profile
Other records with product code QYI
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Recor Medical, Inc. | PMA supplement | Aug 13, 2026 | FDA | |
| Recor Medical, Inc. | PMA supplement | Jul 29, 2026 | FDA | |
ReCor Paradise CatheterP220023/S009 | Recor Medical, Inc. | PMA supplement | Sep 11, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 3576 Unocal Pl., Santa Rosa, CA, 95403
Sources and methodology
- Original FDA record: P220026/S017
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


